Emmes announces reorganization and launch of AI unit
Psychedelic Therapy Faces Regulatory Hurdles Despite Promising Research
Psychedelic Therapy Faces Regulatory Hurdles Despite Promising Research
Key Insights
Go back to Newsroom
Key Insights
A CRO Should be the Partner that Gives Full Visibility on a Gene Therapy Trials Path
A CRO Should be the Partner that Gives Full Visibility on a Gene Therapy Trials Path
Go back to Newsroom
Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD
Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD
Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.
Download Go back to Newsroom
Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.
SCOPE Summit 2025: Emmes' Peter Ronco on Small Biopharma & Clinical Trial Partnerships
SCOPE Summit 2025: Emmes' Peter Ronco on Small Biopharma & Clinical Trial Partnerships
Go back to Newsroom
Large Language Models and Beyond: AI’s Impact on Clinical Trial Efficiency and Integrity
Large Language Models and Beyond: AI’s Impact on Clinical Trial Efficiency and Integrity
Go back to Newsroom
SCOPE Summit 2025: Peter Ronco on the Risks Small Biopharma Companies Face in Clinical Trial Partnerships
SCOPE Summit 2025: Peter Ronco on the Risks Small Biopharma Companies Face in Clinical Trial Partnerships
Go back to Newsroom
SCOPE Summit 2025: Peter Ronco Offers Tips to Small Biopharma Companies on Properly Scaling Clinical Programs
SCOPE Summit 2025: Peter Ronco Offers Tips to Small Biopharma Companies on Properly Scaling Clinical Programs
Go back to Newsroom
Emmes Group Earns ISO 27001:2022 Certification for Data Security
Emmes Group Earns ISO 27001:2022 Certification for Data Security
Emmes Group, a specialized, technology-enabled Contract Research Organization (CRO), has achieved ISO/IEC 27001:2022 certification after a rigorous audit. This data security certificate, widely regarded as the gold standard for Information Security Management Systems (ISMS), guarantees that Emmes Group and its subsidiary companies, Emmes and Veridix, adhere to the highest global standards for safeguarding sensitive information across its workforce, processes, and technology.
Download Go back to Newsroom
Emmes Group, a specialized, technology-enabled Contract Research Organization (CRO), has achieved ISO/IEC 27001:2022 certification after a rigorous audit. This data security certificate, widely regarded as the gold standard for Information Security Management Systems (ISMS), guarantees that Emmes Group and its subsidiary companies, Emmes and Veridix, adhere to the highest global standards for safeguarding sensitive information across its workforce, processes, and technology.